NEW YORK, April 4, 2024 /PRNewswire/ -- Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, today announced that it has entered into a collaboration agreement with Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers. Under the terms of the agreement, Aethon will use its HapImmune™ platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines' RAS(ON) inhibitors, with the goal of fueling tumor clearance and helping to establish immune memory.